Fonar ROE 2006-2018 | FONR
Current and historical return on equity (ROE) values for Fonar (FONR) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Fonar ROE for the three months ending December 31, 2018 was 18.40%.
| Fonar ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2018-12-31 | $0.02B | $0.11B | 17.48% |
| 2018-09-30 | $0.02B | $0.11B | 19.39% |
| 2018-06-30 | $0.02B | $0.10B | 20.49% |
| 2018-03-31 | $0.02B | $0.09B | 18.18% |
| 2017-12-31 | $0.02B | $0.09B | 22.75% |
| 2017-09-30 | $0.02B | $0.09B | 24.28% |
| 2017-06-30 | $0.02B | $0.08B | 25.94% |
| 2017-03-31 | $0.02B | $0.08B | 28.04% |
| 2016-12-31 | $0.02B | $0.07B | 25.20% |
| 2016-09-30 | $0.02B | $0.07B | 24.90% |
| 2016-06-30 | $0.02B | $0.06B | 26.32% |
| 2016-03-31 | $0.01B | $0.06B | 25.69% |
| 2015-12-31 | $0.01B | $0.06B | 25.12% |
| 2015-09-30 | $0.01B | $0.05B | 23.88% |
| 2015-06-30 | $0.01B | $0.05B | 22.45% |
| 2015-03-31 | $0.01B | $0.05B | 20.94% |
| 2014-12-31 | $0.01B | $0.05B | 21.39% |
| 2014-09-30 | $0.01B | $0.05B | 22.35% |
| 2014-06-30 | $0.01B | $0.05B | 23.39% |
| 2014-03-31 | $0.01B | $0.04B | 24.54% |
| 2013-12-31 | $0.01B | $0.04B | 23.23% |
| 2013-09-30 | $0.01B | $0.04B | 25.20% |
| 2013-06-30 | $0.01B | $0.04B | 28.00% |
| 2013-03-31 | $0.00B | $0.04B | 21.92% |
| 2012-12-31 | $0.00B | $0.01B | 32.65% |
| 2012-09-30 | $0.00B | $0.01B | 36.36% |
| 2012-06-30 | $0.00B | $0.01B | 42.11% |
| 2012-03-31 | $0.00B | $0.01B | 36.36% |
| 2011-12-31 | $0.00B | $0.01B | 57.14% |
| 2011-09-30 | $0.00B | $0.01B | 150.00% |
| 2011-06-30 | $0.00B | $0.01B | -200.00% |
| 2011-03-31 | $0.00B | $-0.00B | -50.00% |
| 2010-12-31 | $0.00B | $-0.00B | -19.05% |
| 2010-09-30 | $-0.00B | $-0.01B | 17.39% |
| 2010-06-30 | $-0.00B | $-0.01B | 52.17% |
| 2010-03-31 | $-0.00B | $-0.01B | 60.00% |
| 2009-12-31 | $-0.00B | $-0.01B | 47.06% |
| 2009-09-30 | $0.00B | $-0.01B | 0.00% |
| 2009-06-30 | $0.00B | $-0.00B | -53.33% |
| 2009-03-31 | $-0.01B | $-0.00B | 125.00% |
| 2008-12-31 | $-0.01B | $-0.00B | 360.00% |
| 2008-09-30 | $-0.01B | $-0.01B | 5600.00% |
| 2008-06-30 | $-0.01B | $-0.00B | -430.77% |
| 2008-03-31 | $-0.02B | $0.00B | -246.15% |
| 2007-12-31 | $-0.02B | $0.01B | -180.00% |
| 2007-09-30 | $-0.02B | $0.01B | -131.03% |
| 2007-06-30 | $-0.03B | $0.01B | -129.87% |
| 2007-03-31 | $-0.03B | $0.02B | -102.04% |
| 2006-12-31 | $-0.03B | $0.02B | -90.76% |
| 2006-09-30 | $-0.03B | $0.03B | -77.14% |
| 2006-06-30 | $-0.03B | $0.03B | -72.96% |
| 2006-03-31 | $-0.02B | $0.04B | -44.20% |
| 2005-12-31 | $-0.01B | $0.04B | -26.67% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.137B | $0.082B |
| FONAR Corporation is a developer and manufacturer of MRI scanners. The Company has introduced the world's first commercial MRI in 1980, and went public in 1981. FONAR's stellar product is the UPRIGHT MRI, also known as the Stand-Up MRI, the whole-body MRI that performs Position imaging and scans patients in numerous weight-bearing positions like standing, sitting, in flexion and extension, as well as the conventional lie-down position. The Company's subsidiary, Health Management Corporation of America, is a physician practice management company providing management services to medical providers. FONAR Corporation is based in Melville, New York. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $136.952B | 27.07 |
| Medtronic (MDT) | Ireland | $121.227B | 17.72 |
| Stryker (SYK) | United States | $72.547B | 26.60 |
| Boston Scientific (BSX) | United States | $51.696B | 25.20 |
| Baxter (BAX) | United States | $39.588B | 25.33 |
| Zimmer Biomet Holdings (ZBH) | United States | $25.898B | 16.58 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $17.446B | 0.00 |
| Canopy Growth (CGC) | Canada | $14.852B | 0.00 |
| ResMed (RMD) | United States | $14.350B | 27.21 |
| Bio-Rad Laboratories (BIO) | United States | $9.156B | 52.24 |
| Aurora Cannabis (ACB) | Canada | $9.141B | 64.50 |
| Hill-Rom Holdings (HRC) | United States | $6.962B | 21.53 |
| Perrigo (PRGO) | Ireland | $6.420B | 10.41 |
| Insulet (PODD) | United States | $5.800B | 1956.80 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $5.092B | 0.00 |
| ICU Medical (ICUI) | United States | $4.698B | 29.24 |
| Haemonetics (HAE) | United States | $4.311B | 38.24 |
| Hutchison China MediTech (HCM) | China | $3.810B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $3.637B | 0.00 |
| Neogen (NEOG) | United States | $3.108B | 47.74 |
| NuVasive (NUVA) | United States | $2.892B | 25.23 |
| Quidel (QDEL) | United States | $2.514B | 22.68 |
| Aphria (APHA) | $2.385B | 105.89 | |
| National Vision Holdings (EYE) | United States | $2.274B | 44.72 |
| Cardiovascular Systems (CSII) | United States | $1.346B | 966.50 |
| Phibro Animal Health (PAHC) | United States | $1.283B | 18.45 |
| VAREX IMAGING (VREX) | United States | $1.275B | 24.96 |
| AtriCure (ATRC) | United States | $1.081B | 0.00 |
| MacroGenics (MGNX) | United States | $0.926B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $0.911B | 24.60 |
| Cerus (CERS) | United States | $0.844B | 0.00 |
| PetIQ (PETQ) | United States | $0.831B | 23.77 |
| Omeros (OMER) | United States | $0.828B | 0.00 |
| NanoString Technologies (NSTG) | United States | $0.729B | 0.00 |
| Meridian Bioscience (VIVO) | United States | $0.715B | 21.30 |
| OraSure Technologies (OSUR) | United States | $0.664B | 29.11 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.657B | 22.35 |
| Evolus (EOLS) | United States | $0.655B | 0.00 |
| TG Therapeutics (TGTX) | United States | $0.601B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $0.596B | 28.35 |
| Surmodics (SRDX) | United States | $0.563B | 81.90 |
| Quanterix (QTRX) | United States | $0.518B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.364B | 150.23 |
| Vapotherm (VAPO) | United States | $0.335B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.331B | 0.00 |
| Insys Therapeutics (INSY) | United States | $0.328B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.300B | 19.49 |
| Owens & Minor (OMI) | United States | $0.271B | 3.76 |
| Bovie Medical (APYX) | United States | $0.260B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.241B | 0.00 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.238B | 0.00 |
| Zynex (ZYXI) | United States | $0.145B | 15.52 |
| Surface Oncology (SURF) | United States | $0.116B | 0.00 |
| Chimerix (CMRX) | United States | $0.102B | 0.00 |
| Female Health (VERU) | United States | $0.100B | 0.00 |
| Chembio Diagnostics (CEMI) | United States | $0.096B | 0.00 |
| United-Guardian (UG) | United States | $0.087B | 19.84 |
| CAS Medical Systems (CASM) | United States | $0.072B | 0.00 |
| Neurotrope (NTRP) | United States | $0.065B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.058B | 17.14 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.056B | 0.00 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.039B | 0.00 |
| ImmuCell (ICCC) | United States | $0.038B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.035B | 0.00 |
| Senestech (SNES) | United States | $0.029B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.018B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.016B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.013B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.011B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 15.29 |
